Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2632 • ACR Convergence 2025
Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies
ANA JIMENA LOPEZ DIAZ¹, MARIA DEL CARMEN ZAMORA MEDINA², Mario Isaac Lumbreras Márquez¹, Diana Yazmin Copado mendoza¹, Oralia Alejandra Orozco Guillén¹, Maria José rodríguez Sibaja¹, Martha Leticia Palafox Vargas¹ and Sandra Acevedo gallegos¹, ¹Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Perinatologia, Mexico City, Distrito Federal, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse perinatal outcomes (APOs), including preeclampsia, preterm birth, fetal growth restriction, and stillbirth. Placental…
Abstract Number: 2547 • ACR Convergence 2025
Assessing the Reach of a Virtual Education Program: Lupus & You: Answers. Advocacy. Action.
Ashley Holden, Wendy Rodgers, Khadija Dantata, Lety Ocana and Guadalupe Patino, The Lupus Foundation of America, Washington, DC
Background/Purpose: Comprehensive lupus education is essential for increasing awareness, early diagnosis and management of lupus due to the disease’s heterogenous nature. The Lupus Foundation of…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 2437 • ACR Convergence 2025
Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Aaron Smith¹, Thuyvan Phan², Leah Luizza³, Anthony Trujillo³, Becki Cleveland¹, Shruti Saxena Beem⁴, Tessa Englund⁵, Claire Timon⁴ and Saira Sheikh⁵, ¹University of North Carolina, Chapel Hill, NC, ²UNC Health, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, ⁴University of North Carolina at Chapel Hill, Chapel Hill, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease with heterogenous presentation. Most patients with SLE report fatigue or brain fog, which often…
Abstract Number: 2418 • ACR Convergence 2025
ORF1p Expression Correlates with STING Activation and IFN Signatures in SLE Nonlesional Skin
Mehrnaz Gharaee-Kermani¹, Svenja Henning², John LaCava³, Tomas Mustelin⁴ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Groningen, Groningen, Groningen, Netherlands, ³Rockefeller University, New York City, NY, NJ, ⁴University of Washington, Seattle, WA
Background/Purpose: Type I interferons (IFNs) are elevated in the skin and blood of patients with systemic (SLE) and cutaneous (CLE) lupus erythematosus. Upregulation of type…
Abstract Number: 2402 • ACR Convergence 2025
High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Alexander Tsoi¹, Dionysis Nikolopoulos², Natalia Sherina³ and Ioannis Parodis¹, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ³Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, and Karolinska University Hospital, Stockholm, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Belimumab, a BAFF inhibitor, is an effective treatment for systemic lupus erythematosus (SLE), but biomarkers predicting treatment response remain elusive. We aimed to identify…
Abstract Number: 2384 • ACR Convergence 2025
Patient-Reported Quality of Life in SLE: Association with Biomarker-Derived Disease Activity Index (L-DAI) and hSLEDAI in a Prospective Cohort
Bernard Rubin¹, Rou Sore¹, Melissa Munroe¹, Daniele DeFreese¹, Adrian Holloway¹, Mohan Purushothaman¹, Yangfen Li², Hu Zeng², Uma Thanarajasingam², Judith James³ and Eldon Jupe¹, ¹Progentec Diagnostics, Inc., Oklahoma City, OK, ²Mayo Clinic, Rochester, MN, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by unpredictable disease activity. The Lupus Disease Activity Index (L-DAI) is a blood-based assessment…
Abstract Number: 2215 • ACR Convergence 2025
Placenta Abnormalities in Systemic Lupus Erythematosus: Novel Marker of Adverse Pregnancy Outcomes
Kaitlin Nuechterlein¹, Karl Grenier¹, Luisa Ciofani², Kalliopi Panaritis², Sasha Bernatsky² and Evelyne Vinet², ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Placenta-mediated adverse pregnancy outcomes (APO) are a huge concern in SLE. Recent efforts to understand APO include the establishment of the 2016 Amsterdam classification…
Abstract Number: 1975 • ACR Convergence 2025
Baseline QTc Screening and Monitoring Among SARD Patients with High Cardiovascular Risks on Hydroxychloroquine Based on 2021 ACR Consensus: A Quality Improvement Project
Cristine Kuzhuppilly Arcilla¹, Gabriel Kirsch², Gurjit Kaeley³ and Myint Thway⁴, ¹University of Florida Jacksonville, Jacksonville, FL, ²University of Florida - Jacksonville, Jacksonville, FL, ³UF COM-J, Ponte Vedra Beach, FL, ⁴UF Jacksonville, ponte vedra, FL
Background/Purpose: In 2017, FDA approved warnings regarding fatal cardiac effects such as cardiomyopathy, torsades de pointes, and QTc prolongation related to both acute and chronic…
Abstract Number: 1853 • ACR Convergence 2025
SAP Expression in SLE T Cells is Associated with Differentiation Towards Pro-Inflammatory Effector Subsets.
Yevgeniya Gartshteyn¹, Daniel Portnoy², Matthieu Paiola³, Anca Askanase² and Adam Mor⁴, ¹Columbia University Medical Center, Glen Rock, NJ, ²Columbia University Medical Center, New York, NY, ³Columbia University Irving Medical Center, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: SAP is an adaptor protein that mediates signaling downstream of SLAMF T cell receptors. SAP deficiency results in X-linked Lymphoproliferative immunodeficiency characterized by impaired…
Abstract Number: 1834 • ACR Convergence 2025
Integrative Bioinformatics Analysis Reveals Key Genes and Immune Profiles Associated with Preeclampsia in Lupus Pregnancy
Rodolfo Martinez-Canales¹, Eva Abigaid Galindo-Calvillo², Andres M. Ortiz-Rios², Braulio R. Avalos-Garcia², Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³, Cassandra Michele Skinner-Taylor², Mario Cesar Salinas-Carmona¹ and Noe Macias-Segura¹, ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Preeclampsia (PE) is a serious complication of pregnancy associated with significant maternal and fetal outcomes. Systemic lupus erythematosus (SLE) significantly increases the risk of…
Abstract Number: 1742 • ACR Convergence 2025
S100B in Childhood-onset Systemic Lupus Erythematosus: Associations with Disease Features, Interferon Levels, and Cognitive Functioning
Ganesh Ramanathan¹, Justine Ledochowski², Oscar Mwizerwa³, Tala El Tal⁴, Lawrence Ng⁵, Asha Jeyanathan⁶, Adrienne Davis⁶, Ann Yeh⁶, Linda Hiraki², Deborah Levy², Zahi Touma⁷, Joan Wither⁸, Busisiwe Zapparoli⁹, Ashley Danguecan¹⁰ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Brampton, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸University Health Network, Toronto, ON, Canada, ⁹The Hospital for Sick Children, Etobicoke, ON, Canada, ¹⁰Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Cognitive impairment is common in childhood-onset systemic lupus erythematosus (cSLE), particularly in domains like executive function and attention. However, attributing cognitive difficulties to brain…
Abstract Number: 1686 • ACR Convergence 2025
The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Sofia Pedro² and Kaleb Michaud³, ¹UCSF, San Rafael, CA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Depression is reported to be common in SLE, but little is known about depressive symptoms among older adults with SLE. While the burden of…
Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Susan Manzi¹, Ian Bruce², Eric Morand³, Richard Furie⁴, Yoshiya Tanaka⁵, Patricia Puzio⁶, Emon Khan⁷, Jenny Wissmar⁸, Michael Song⁹ and Catharina Lindholm¹⁰, ¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁴Division of Rheumatology, Northwell Health, Great Neck, NY, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, ¹⁰BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
Abstract Number: 1525 • ACR Convergence 2025
Rituximab super-responders: characteristics of patients with more than 3 years response to a single cycle of treatment
Md Yuzaiful Md Yusof¹, Junaid Patel², Paul Emery³ and Ed Vital³, ¹University of Leeds, Leeds, United Kingdom, ²University of Leeds, Leeds, ³University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Emerging therapies such as CD19 CAR-T-cells have been reported to induce deeper B-cell depletion and thereby drug-free remission up to 18 months. With rituximab,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].